KODIAK SCIENCES INC. (KOD) Current Ratio
- Current ratio · latest quarter: Value 2.49×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.49× | Current assets / current liabilities. $131.36M ÷ $52.77M ≈ 2.49× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 131.36M USD | Assets, Current |
| Current obligations | 52.77M USD | Liabilities, Current |
| Cash and equivalents | 125.90M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 12.64M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $131.36M | $52.77M | $125.90M | (m) | (m) | (m) | $12.64M | (m) | 2.49× |
| 2026-03-31 | $175.26M | $49.57M | $169.53M | (m) | (m) | (m) | $11.34M | (m) | 3.54× |
| 2025-12-31 | $214.82M | $45.53M | $209.86M | (m) | (m) | (m) | $12.86M | (m) | 4.72× |
| 2025-09-30 | $75.73M | $42.43M | $72.04M | (m) | (m) | (m) | $10.37M | (m) | 1.78× |
| 2025-06-30 | $107.92M | $31.01M | $104.17M | (m) | (m) | (m) | $5.06M | (m) | 3.48× |
| 2025-03-31 | $142.69M | $30.88M | $138.85M | (m) | (m) | (m) | $6.54M | (m) | 4.62× |
| 2024-12-31 | $171.94M | $25.57M | $168.07M | (m) | (m) | (m) | $3.92M | (m) | 6.72× |
| 2024-09-30 | $202.49M | $24.06M | $197.86M | (m) | (m) | (m) | $3.29M | (m) | 8.42× |
| 2024-06-30 | $224.63M | $21.20M | $219.22M | (m) | (m) | (m) | $1.87M | (m) | 10.59× |
| 2024-03-31 | $251.51M | $24.86M | $245.92M | (m) | (m) | (m) | $2.48M | (m) | 10.12× |
| 2023-12-31 | $289.31M | $41.73M | $285.51M | (m) | (m) | (m) | $13.61M | (m) | 6.93× |
| 2023-09-30 | $350.93M | $70.77M | $345.67M | $0.00 | (m) | (m) | $38.59M | (m) | 4.96× |
| 2023-06-30 | $386.96M | $74.24M | $378.67M | $0.00 | (m) | (m) | $12.35M | (m) | 5.21× |
| 2023-03-31 | $431.12M | $68.94M | $316.62M | $104.58M | (m) | (m) | $6.26M | (m) | 6.25× |
| 2022-12-31 | $486.00M | $52.50M | $190.43M | $288.50M | (m) | (m) | $9.13M | (m) | 9.26× |
| 2022-09-30 | $544.66M | $65.60M | $178.41M | $358.98M | (m) | (m) | $15.61M | (m) | 8.30× |
| 2022-06-30 | $604.37M | $69.83M | $172.69M | $425.18M | (m) | (m) | $20.63M | (m) | 8.65× |
| 2022-03-31 | $682.19M | $76.33M | $671.73M | (m) | (m) | (m) | $13.07M | (m) | 8.94× |
| 2021-12-31 | $734.81M | $64.68M | $731.51M | $0.00 | (m) | (m) | $12.43M | (m) | 11.36× |
| 2021-09-30 | $805.51M | $54.40M | $799.25M | (m) | (m) | (m) | $13.76M | (m) | 14.81× |
| 2021-06-30 | $884.33M | $41.02M | $880.87M | $0.00 | (m) | (m) | $2.74M | (m) | 21.56× |
| 2021-03-31 | $931.90M | $35.06M | $920.46M | $8.52M | (m) | (m) | $9.18M | (m) | 26.58× |
| 2020-12-31 | $972.00M | $31.42M | $944.40M | $24.58M | (m) | (m) | $8.65M | (m) | 30.93× |
| 2020-09-30 | $381.75M | $22.50M | $291.58M | $88.86M | (m) | (m) | $5.27M | (m) | 16.96× |
| 2020-06-30 | $419.01M | $18.77M | $269.84M | $147.30M | (m) | (m) | $7.03M | (m) | 22.32× |
| 2020-03-31 | $424.81M | $13.83M | $226.46M | $195.40M | (m) | (m) | $4.51M | (m) | 30.71× |
| 2019-12-31 | $339.23M | $11.71M | $211.80M | $124.68M | (m) | (m) | $2.62M | (m) | 28.97× |
| 2019-09-30 | $61.04M | $7.30M | $37.03M | $23.57M | (m) | (m) | $1.67M | (m) | 8.36× |
| 2019-06-30 | $70.49M | $6.21M | $44.97M | $23.13M | (m) | (m) | $2.53M | (m) | 11.34× |
| 2019-03-31 | $83.28M | $4.77M | $57.22M | $23.85M | (m) | (m) | $1.75M | (m) | 17.45× |
| 2018-12-31 | $90.45M | $4.83M | $88.25M | (m) | (m) | (m) | $1.05M | (m) | 18.74× |
| 2018-09-30 | $12.29M | $5.38M | $11.59M | (m) | (m) | (m) | $1.72M | (m) | 2.28× |
| 2017-12-31 | $1.59M | $9.16M | $1.40M | (m) | (m) | (m) | $3.36M | (m) | 0.17× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |